Back to resultsVolatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Primary Purpose
Colonic Cancer, Rectal Cancer, Non Small Cell Lung Cancer
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Sevoflurane
Propofol
Lidocaine IV
Sponsored by
About this trial
This is an interventional other trial for Colonic Cancer
Eligibility Criteria
Inclusion Criteria:
- Male or female patients aged 18 years or older at screening
- Has provided written informed consent for the trial
- Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis. In cases where a histological diagnosis is not possible, suspected diagnosis through imaging techniques is acceptable.
- Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3
- Scheduled to receive elective, surgical resection with curative intent
- Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay
- Able to comply with protocol requirements and follow-up procedures
Exclusion Criteria:
- Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine
- Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score >Class A;
- Patient at personal or familial risk of malignant hyperthermia or porphyria
- Patient with a history of other malignancies within the past 5 years. However, patients with malignancies managed with curative therapy and considered to be at low risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma, malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer, cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade prostate and breast cancer) may be included in the study
- Patient has distant metastases
- Patient with an actual body weight less than 45kg
- Patients taking the following drugs that are moderate-strong inhibitors of the CYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics - 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within a bowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other: Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir; Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir. Antidepressants/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem, Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Other strong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice, Mifepristone, Nefazodone.
Sites / Locations
- Cleveland ClinicRecruiting
- University of Pittsburgh Medical Center
- The University of Texas MD Anderson Cancer CentreRecruiting
- Chris O'Brien Lifehouse
- Royal Prince Alfred HospitalRecruiting
- Prince of Wales HospitalRecruiting
- Royal Brisbane and Women's HospitalRecruiting
- Mackay Base HospitalRecruiting
- RedCliffe HospitalRecruiting
- Rockhampton HospitalRecruiting
- Gold Coast University HospitalRecruiting
- Princess Alexandra HospitalRecruiting
- Royal Adelaide HospitalRecruiting
- Royal Hobart Hospital
- Ballarat Base HospitalRecruiting
- Box Hill HospitalRecruiting
- Northern Hospital
- St Vincent's Hospital, MelbourneRecruiting
- Western Health Footscray HospitalRecruiting
- Austin HealthRecruiting
- Peter MacCallum Cancer CentreRecruiting
- The Alfred HospitalRecruiting
- The Royal Melbourne HospitalRecruiting
- Goulburn Valley HealthRecruiting
- Northeast Health, WangarattaRecruiting
- North Shore Hospital
- Auckland City HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
A
B
C
D
Arm Description
Sevoflurane + intravenous lidocaine
Sevoflurane
Propofol TIVA + intravenous lidocaine
Propofol TIVA
Outcomes
Primary Outcome Measures
Comparison of disease free survival (DFS) with propofol-TIVA versus sevoflurane
The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.
Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine
The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.
Secondary Outcome Measures
Comparison of overall survival (OS) with propofol-TIVA versus sevoflurane
The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.
Days alive and at home with propofol-TIVA versus sevoflurane
Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.
Overall survival with intravenous lidocaine versus no lidocaine
The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.
Days alive and at home with intravenous lidocaine versus no lidocaine
Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.
Comparison of post-operative complications with propofol-TIVA versus sevoflurane
Short term postoperative morbidity assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading.
POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades.
Comparison of post-operative complications with intravenous lidocaine versus no lidocaine
Short term postoperative morbidity assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading.
POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades.
Comparison of chronic post surgical pain with propofol-TIVA versus sevoflurane
Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.
Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.
Comparison of chronic post surgical pain with intravenous lidocaine versus no lidocaine
Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.
Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.
Safety profile of propofol-TIVA versus sevoflurane
Toxicities measured using CTCAE V 5 .0
Safety Profile intravenous lidocaine versus no lidocaine
Toxicities measured using CTCAE V 5 .0
Concomitant medication use with propofol-TIVA versus sevoflurane
From 2 weeks prior to surgery up to Day 5 post-surgery administration of relevant medications will be recorded
Concomitant medications use with intravenous lidocaine versus no lidocaine
From 2 weeks prior to surgery up to Day 5 post-surgery administration of relevant medications will be recorded
Health utility with propofol-TIVA versus sevoflurane
The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced.
Health utility with intravenous lidocaine versus no lidocaine
The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced
Full Information
NCT ID
NCT04316013
First Posted
January 22, 2020
Last Updated
March 21, 2023
Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborators
National Health and Medical Research Council, Australia, Australian and New Zealand College of Anaesthetists, Victorian Comprehensive Cancer Centre
1. Study Identification
Unique Protocol Identification Number
NCT04316013
Brief Title
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Official Title
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 31, 2020 (Actual)
Primary Completion Date
December 2027 (Anticipated)
Study Completion Date
June 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborators
National Health and Medical Research Council, Australia, Australian and New Zealand College of Anaesthetists, Victorian Comprehensive Cancer Centre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.
Detailed Description
VAPOR-C is a pragmatic, event-driven, randomised controlled trial, with a single blind 2x2 factorial design for sevoflurane/propofol and for intravenous lidocaine infusion / no lidocaine infusion.
This trial is designed to test for superiority in disease free survival (DFS) of propofol (total intravenous anaesthesia -TIVA) over sevoflurane (inhalational volatile anaesthesia) and intravenous lidocaine over no lidocaine in patients undergoing surgery for colorectal or non small cell lung cancer (NSCLC). The combination of two cancer types will help address the need to demonstrate the effects of anaesthetic technique across cancers to inform generalisable anaesthesia guidelines. Both NSCLC and colorectal cancer are important for this study due to high incidence rate, many longer-term survivors, and importantly the high risk of local or distant recurrence despite complete surgical resection. In addition, the study will collect additional data in a nested cohort related to the exploratory objectives.
The study aims to recruit 3,500 patients in Australia, New Zealand, Canada, United States and Europe.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colonic Cancer, Rectal Cancer, Non Small Cell Lung Cancer
7. Study Design
Primary Purpose
Other
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This is an event-driven, international multicentre, randomised controlled trial with a 2x2 factorial design. Patients with stage I-III colorectal cancer or stage I-IIIa NSCLC are eligible and will be randomised in the ratio of 1:1:1:1 using permuted block randomisation with stratification by cancer type (Colon, Rectal or NSCLC), and by site to receive either 1) sevoflurane maintenance anaesthesia and lidocaine infusion or 2) sevoflurane maintenance anaesthesia; or 3), propofol maintenance anaesthesia and lidocaine infusion or 4), propofol maintenance anaesthesia .
Masking
Participant
Masking Description
The propofol-TIVA/sevoflurane element of each arm will have a single blind (patient blinded), as the administering anesthesiologist cannot be blinded to allocation. The lidocaine infusion or no lidocaine infusion element of each ARM will be blinded to the patient . The anaesthetic team and research team caring for the patient will not be blinded to the lidocaine infusion/no lidocaine infusion element of the randomisation ARM
Allocation
Randomized
Enrollment
3500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Active Comparator
Arm Description
Sevoflurane + intravenous lidocaine
Arm Title
B
Arm Type
Active Comparator
Arm Description
Sevoflurane
Arm Title
C
Arm Type
Active Comparator
Arm Description
Propofol TIVA + intravenous lidocaine
Arm Title
D
Arm Type
Active Comparator
Arm Description
Propofol TIVA
Intervention Type
Drug
Intervention Name(s)
Sevoflurane
Intervention Description
Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
Intervention Type
Drug
Intervention Name(s)
Propofol
Intervention Description
Intravenous anaesthetic used for induction and maintenance of anaesthesia
Intervention Type
Drug
Intervention Name(s)
Lidocaine IV
Intervention Description
1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
Primary Outcome Measure Information:
Title
Comparison of disease free survival (DFS) with propofol-TIVA versus sevoflurane
Description
The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.
Time Frame
Until 3 years from participant index surgery date
Title
Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine
Description
The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.
Time Frame
Until 3 years from participant index surgery date
Secondary Outcome Measure Information:
Title
Comparison of overall survival (OS) with propofol-TIVA versus sevoflurane
Description
The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.
Time Frame
Until 3 years from participant index surgery date
Title
Days alive and at home with propofol-TIVA versus sevoflurane
Description
Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.
Time Frame
30 days post surgery
Title
Overall survival with intravenous lidocaine versus no lidocaine
Description
The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.
Time Frame
Until 3 years from participant index surgery date
Title
Days alive and at home with intravenous lidocaine versus no lidocaine
Description
Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.
Time Frame
30 days post surgery
Title
Comparison of post-operative complications with propofol-TIVA versus sevoflurane
Description
Short term postoperative morbidity assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading.
POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades.
Time Frame
5 days post surgery or at discharge if earlier
Title
Comparison of post-operative complications with intravenous lidocaine versus no lidocaine
Description
Short term postoperative morbidity assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading.
POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades.
Time Frame
5 days post surgery or at discharge if earlier
Title
Comparison of chronic post surgical pain with propofol-TIVA versus sevoflurane
Description
Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.
Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.
Time Frame
At 90 days and 12 months post surgery
Title
Comparison of chronic post surgical pain with intravenous lidocaine versus no lidocaine
Description
Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.
Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.
Time Frame
At 90 days and 12 months post surgery
Title
Safety profile of propofol-TIVA versus sevoflurane
Description
Toxicities measured using CTCAE V 5 .0
Time Frame
during surgery until discharge from Post Anaesthetic Care Unit (PACU) or within the first 4 hours of ICU admission
Title
Safety Profile intravenous lidocaine versus no lidocaine
Description
Toxicities measured using CTCAE V 5 .0
Time Frame
during surgery until discharge from Post Anaesthetic Care Unit (PACU) or within the first 4 hours of ICU admission
Title
Concomitant medication use with propofol-TIVA versus sevoflurane
Description
From 2 weeks prior to surgery up to Day 5 post-surgery administration of relevant medications will be recorded
Time Frame
5 days post anaesthesia
Title
Concomitant medications use with intravenous lidocaine versus no lidocaine
Description
From 2 weeks prior to surgery up to Day 5 post-surgery administration of relevant medications will be recorded
Time Frame
5 days post anaesthesia
Title
Health utility with propofol-TIVA versus sevoflurane
Description
The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced.
Time Frame
At 30 days, 90 days and every 12 months post surgery up to 3 years
Title
Health utility with intravenous lidocaine versus no lidocaine
Description
The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced
Time Frame
At 30 days, 90 days and every 12 months post surgery up to 3 years
Other Pre-specified Outcome Measures:
Title
Comparison of return to intended oncological treatment (RIOT) with propofol-TIVA versus sevoflurane
Description
Data will be collected post surgery regarding post treatment adjuvant therapy given according to plan. A comparison will be made between number of participants receiving post surgery oncological treatment as planned and the number of patients deviating from the plan in each arm of the study.
Time Frame
At 90 days and 12 months post surgery
Title
Comparison of return to intended oncological treatment (RIOT) with intravenous lidocaine versus no lidocaine
Description
Data will be collected post surgery regarding post treatment adjuvant therapy given according to plan. A comparison will be made between number of participants receiving post surgery oncological treatment as planned and the number of patients deviating from the plan in each arm of the study.
Time Frame
At 90 days and 12 months post surgery
Title
Correlative blood studies
Description
Inflammatory markers - Neutrophil to lymphocyte ratio (NLR), Platelet to lymphocyte ratio (PLR), C-reactive protein (CRP) Circulating tumour deoxyribonucleic acid (ctDNA), DNA/RNA, Circulating tumour cells (CTCs), immune profile using flow cytometry and plasma for cytokines These are exploratory transnational research outcomes levels of these biomarkers will be measured over the course of the study and analysed for correlation the study outcomes.
Time Frame
Preop, Day 1, 3 and 5 (if still an inpatient) and at recurrence
Title
Correlative breath biopsy studies
Description
To characterise the effect of anaesthetic agents on perioperative inflammatory changes will measure Targeted Volatile Organic Compounds of the eicosanoid pathway by sampling patients breath (breath biopsy) to monitor inflammatory changes within the pulmonary compartment.
Time Frame
Preop, Day 1, 3 and 5 (if still an inpatient) and at recurrence
Title
MINS Substudy
Description
At sites who agree to participate:
Blood Specimens and 12-Lead ECG - 12 Lead ECGS will be done and blood specimens collected to measure Troponin levels at baseline, Day 1 and Day 2 post op.
Assessment of the predefined diagnostic criteria for MINS and perioperative myocardial infarction on Day 5 or Discharge if earlier Assessment of predefined diagnostic criteria for MINS and myocardial infarction at 30 days post op.
Time Frame
Day 0 to day 30
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients aged 18 years or older at screening
Has provided written informed consent for the trial
Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis. In cases where a histological diagnosis is not possible, suspected diagnosis through imaging techniques is acceptable.
Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3
Scheduled to receive elective, surgical resection with curative intent
Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay
Able to comply with protocol requirements and follow-up procedures
Exclusion Criteria:
Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine
Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score >Class A;
Patient at personal or familial risk of malignant hyperthermia or porphyria
Patient with a history of other malignancies within the past 5 years. However, patients with malignancies managed with curative therapy and considered to be at low risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma, malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer, cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade prostate and breast cancer) may be included in the study
Patient has distant metastases
Patient with an actual body weight less than 45kg
Patients taking the following drugs that are moderate-strong inhibitors of the CYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics - 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within a bowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other: Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir; Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir. Antidepressants/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem, Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Other strong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice, Mifepristone, Nefazodone.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bernhard Riedel, MB.ChB
Phone
+61385597663
Email
bernhard.riedel@petermac.org
First Name & Middle Initial & Last Name or Official Title & Degree
Kim Coleman, MN
Phone
+61385598318
Email
Kimberley.Coleman@petermac.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernhard Riedel, MB.ChB
Organizational Affiliation
Peter MacCallum Cancer Centre, Australia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kamal Maheshwari, MD
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aman Mahajan, MD, PhD, MBA
Facility Name
The University of Texas MD Anderson Cancer Centre
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Cata, MD
Facility Name
Chris O'Brien Lifehouse
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Drakeford
Facility Name
Royal Prince Alfred Hospital
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neil Pillinger
Facility Name
Prince of Wales Hospital
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Bennett
Facility Name
Royal Brisbane and Women's Hospital
City
Herston
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Victoria Eley
Facility Name
Mackay Base Hospital
City
Mackay
State/Province
Queensland
ZIP/Postal Code
4740
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Suresh Singaravelu
Facility Name
RedCliffe Hospital
City
Redcliffe
State/Province
Queensland
ZIP/Postal Code
4020
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mattys Campher
Facility Name
Rockhampton Hospital
City
Rockhampton
State/Province
Queensland
ZIP/Postal Code
4700
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Tripet
Facility Name
Gold Coast University Hospital
City
Southport
State/Province
Queensland
ZIP/Postal Code
4215
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Bourke
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pal Sivalingam
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Painter
Facility Name
Royal Hobart Hospital
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Challis
Facility Name
Ballarat Base Hospital
City
Ballarat Central
State/Province
Victoria
ZIP/Postal Code
3350
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gregory Henderson
Facility Name
Box Hill Hospital
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tarin Ward
Facility Name
Northern Hospital
City
Epping
State/Province
Victoria
ZIP/Postal Code
3076
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darren Lowen
Facility Name
St Vincent's Hospital, Melbourne
City
Fitzroy
State/Province
Victoria
ZIP/Postal Code
3065
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desmond McGlade
Facility Name
Western Health Footscray Hospital
City
Footscray
State/Province
Victoria
ZIP/Postal Code
3011
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Sheridan
Facility Name
Austin Health
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurence Weinberg
Facility Name
Peter MacCallum Cancer Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernhard Riedel
Facility Name
The Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Myles
Facility Name
The Royal Melbourne Hospital
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kate Leslie
Facility Name
Goulburn Valley Health
City
Shepparton
State/Province
Victoria
ZIP/Postal Code
3630
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nigel Dunk
Facility Name
Northeast Health, Wangaratta
City
Wangaratta
State/Province
Victoria
ZIP/Postal Code
3677
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Baird
Facility Name
North Shore Hospital
City
Auckland
ZIP/Postal Code
0620
Country
New Zealand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manson Ku
Facility Name
Auckland City Hospital
City
Auckland
ZIP/Postal Code
2023
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Waylen
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
We'll reach out to this number within 24 hrs